Second Genome’s McClure Joins Aligos as Chief Medical Officer
Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xpertise: Watch + Learn
From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Key indicators & expert insight from industry leaders
Xconomy
From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities
Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex